首頁 > 市場調查報告書 > 醫療設備

導管

市場調查報告書

商品編碼

1736639

2026 年至 2032 年射頻消融設備市場（按產品類型、應用和地區）

Radiofrequency Ablation Devices Market By Product Type (Disposable Equipment, Capital Equipment, Reusable Equipment), By Application (Oncology, Cardiology and Cardiac Rhythm Management, Gynecology, Pain Management), And Region For 2026-2032

出版日期: 2025年05月05日 | 出版商:

Verified Market Research | 英文 202 Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

射頻消融設備市場評估（2026-2032）

射頻消融技術的進步正在推動市場成長。這些技術創新使治療更加可靠、可靠且易於獲取，同時提高了準確性、有效性和安全性。因此，射頻消融技術的進步將呈指數級成長，推動市場規模在2024年超過47.4億美元，到2032年達到100.8億美元的估值。

由於門診手術便捷、經濟高效且住院時間短，越來越受到人們的偏好。射頻消融設備順應了這個趨勢，它提供微創手術，恢復時間極短，對患者和醫療服務提供者來說都是一個相當吸引人的選擇。因此，預計門診病人手術的日益普及將推動市場在2026年至2032年間以10.90%的複合年成長率成長。

射頻消融設備市場定義/概述

射頻消融術 (RFA) 設備是一種專用醫療設備，利用高頻電流產生可控熱量，並作用於特定組織或神經，從而誘導凝固或破壞。這種微創手術廣泛應用於介入放射學、疼痛管理、腫瘤學、心臟病學和皮膚病學等多個醫學領域。 RFA 因其能夠精準定位患處而不損傷周圍組織而備受推崇，使其成為多種疾病的安全有效治療選擇。

RFA 通常用於治療慢性疼痛，例如下背痛或關節痛，以及控制某些類型的癌症、心律不整、靜脈曲張、良性和惡性腫瘤等引起的疼痛。在疼痛管理中，RFA 透過阻斷神經訊號提供持久的緩解，並在腫瘤學和心臟病學中用於消融腫瘤和異常的心臟組織。

射頻消融術 (RFA) 設備的持續技術進步旨在改善其設計、增強其能量傳輸系統並提高手術效率。這些創新正在提高治療精準度、縮短恢復時間並擴大射頻消融 (RFA) 可治療的疾病範圍。研究也致力於擴展射頻消融術 (RFA) 的應用範圍，以治療新的疾病並改善治療通訊協定，使射頻消融術 (RFA) 成為現代醫療干預的重要工具。

人口老化和慢性病負擔的增加將如何推動射頻消融設備市場的成長？

全球人口老化和慢性病數量的增加正在推動射頻消融市場的成長。根據世界衛生組織預測，2050年，全球60歲以上人口將達到21億人。美國疾病管制與預防中心報告稱，截至2022年，85%的老年人至少患有一種慢性病，60%的老年人將患有兩種或兩種以上的慢性病。由於老年人口的成長，2020年至2022年間，醫療保險在射頻消融治療上的支出增加了32%。

美國) 報告稱，2021 年將新增 190 萬例癌症病例，其中肝癌病例年成長率為 2.5%。根據 GLOBOCAN 2022 報告，射頻消融 (RFA) 療法在早期肝癌治療中約佔 25%。 RFA 在小肝細胞癌病例中的臨床成功率據稱高達 97%。美國心臟協會 (美國 Heart Association) 報告稱，2022 年將進行超過 45 萬例心導管電氣燒灼術手術，較 2020 年成長 15%。聯邦醫療保險 (Medicare) 數據顯示，2020 年至 2023 年間，心臟射頻消融手術的報銷申請將增加 28%。

美國食品藥物管理局（FDA）在2021年至2023年間核准了八種新型射頻消融術（RFA）設備。介入放射學會（ISRA）報告稱，2022年新型RFA系統將手術時間縮短了40%。 2020年至2023年，醫院採用先進RFA系統的比例增加了35%。《美國管理式醫療雜誌》（American Journal of Managed Care）報告稱，2022年RFA比傳統手術費用降低45%。根據2023年醫療保健成本與利用計畫（HCUP）的數據，平均住院時間從5.2天（手術）減少到1.3天（RFA）。保險理賠數據顯示，RFA的總治療費用比傳統手術低30%。

有限的熟練醫護人員如何阻礙射頻消融設備市場的成長？

美國麻醉師協會 ( 美國 Society of Anesthesiologists) 報告稱，2022 年，經過培訓的射頻消融 (RFA) 專家短缺率將達到 22%。美國醫學院協會 (Association of 美國 Medical Colleges) 的數據顯示，截至 2023 年，只有 35% 的介入放射科醫師將接受高階射頻消融 (RFA) 技術培訓。從 2020 年到 2022 年，RFA 手術的訓練成本將上漲 45%，這將限制小型醫療中心的採用（介入放射學會 (Society of Intervention Radiology)）。 2023 年，一台 RFA 機器的平均成本將達到 8.5 萬至 17.5 萬美元。根據美國醫療保險和醫療補助服務中心 (CMS) 的數據，醫療保險報銷僅能涵蓋手術總費用的 60% 至 70%。

由於預算限制，2022 年醫院對 RFA 設備的投資下降了 18%。

美國食品藥物管理局 (FDA) 報告稱，2020 年至 2022 年間，與射頻消融術 (RFA) 手術相關的不利事件報告增加了 15%。臨床研究發現，心臟射頻消融術 (RFA) 手術的併發症發生率為 4.7%（美國心臟協會，2023 年）。複雜性腫瘤消融病例的技術失敗率為 8.3%（《介入放射學期刊》，2022 年）。 2022 年，FDA 對新型射頻消融設備的核准時間平均為 18 個月，而其他醫療設備的核准時間平均為 12 個月。 2020 年至 2023 年間，監管合規成本增加了 28%（醫療設備製造商協會）。

Advancements in radiofrequency ablation technology are fueling market growth. These innovations have enhanced the precision, efficacy, and safety of treatments, making them more reliable and accessible. Thus, advancements in radiofrequency ablation technology surge the growth of market size surpassing USD 4.74 Billion in 2024 to reach a valuation of USD 10.08 Billion by 2032.

The growing preference for outpatient procedures is driven by their convenience, cost-effectiveness, and shorter hospital stays. Radiofrequency ablation devices, being minimally invasive, align with this trend by offering procedures that require minimal recovery time, making them an attractive option for both patients and healthcare providers. Thus, the increasing popularity of outpatient procedures enables the market to grow at a CAGR of 10.90% from 2026 to 2032.

Radiofrequency Ablation Devices Market: Definition/ Overview

Radiofrequency ablation (RFA) devices are specialized medical instruments that utilize high-frequency electrical currents to generate controlled heat, which is applied to specific tissues or nerves to induce coagulation or destruction. This minimally invasive procedure is widely used across various medical disciplines, including interventional radiology, pain management, oncology, cardiology, and dermatology. RFA is particularly valued for its ability to precisely target affected areas without damaging surrounding tissues, making it a safe and effective treatment option for several conditions.

Common applications of RFA include the treatment of chronic pain conditions, such as back pain and joint pain, as well as the management of specific types of cancer, cardiac arrhythmias, varicose veins, and both benign and malignant tumors. In pain management, RFA offers long-lasting relief by disrupting nerve signals, while in oncology and cardiology, it is used to ablate tumors or aberrant heart tissue.

Ongoing technological advancements in RFA devices aim to improve their design, enhance energy delivery systems, and increase procedural efficiency. These innovations are enhancing treatment precision, reducing recovery times, and expanding the range of conditions that can be treated with RFA. Research is also focused on broadening the applications of RFA to target new medical conditions and refine treatment protocols, positioning RFA as a crucial tool in modern medical interventions.

How does the Growing Geriatric Population & Chronic Disease Burden Surge the Growth of the Radiofrequency Ablation Devices Market?

An increasing aging population and rising chronic disorders globally propel the growth of the radiofrequency ablation devices market. According to the WHO, the global population aged 60+ will reach 2.1 billion by 2050 The CDC reported that 85% of older adults have at least one chronic condition, with 60% having two or more as of 2022. Medicare spending on RF ablation procedures increased by 32% between 2020-2022 due to rising elderly population demands

The National Cancer Institute reported 1.9 million new cancer cases in 2021, with liver cancer cases increasing by 2.5% annually. According to GLOBOCAN 2022, RF ablation was used in approximately 25% of early-stage liver cancer treatments. Clinical success rates of 97% were reported for RF ablation in small hepatocellular carcinoma cases. The American Heart Association reported 450,000+ cardiac ablation procedures in 2022, a 15% increase from 2020. Medicare data showed a 28% increase in reimbursement claims for cardiac RF ablation procedures between 2020-2023

FDA approved 8 new RF ablation devices between 2021-2023. The Society of Interventional Radiology reported a 40% reduction in procedure time with newer RF ablation systems in 2022. Hospital adoption of advanced RF ablation systems increased by 35% from 2020 to 2023. The American Journal of Managed Care reported 45% lower costs for RF ablation compared to traditional surgery in 2022. Average hospital stay reduced from 5.2 days (surgery) to 1.3 days (RF ablation) according to the Healthcare Cost and Utilization Project (HCUP) 2023. Insurance claims data showed 30% lower total treatment costs with RF ablation versus conventional surgery.

How do Limited Skilled Healthcare Professionals Impede the Growth of the Radiofrequency Ablation Devices Market?

The American Society of Anesthesiologists reported a 22% shortage of trained RF ablation specialists in 2022. According to the Association of American Medical Colleges, only 35% of interventional radiologists are trained in advanced RF ablation techniques as of 2023. Training costs for RF ablation procedures increased by 45% from 2020 to 2022, limiting adoption in smaller healthcare facilities (Society of Interventional Radiology). The average cost of RF ablation equipment ranges from $85,000 to $175,000 as of 2023. Medicare reimbursement covers only 60-70% of the total procedure cost, according to CMS data 2022

Hospital investment in RF ablation equipment decreased by 18% in 2022 due to budget constraints.

The FDA reported a 15% increase in adverse event reports related to RF ablation procedures from 2020 to 2022. Clinical studies showed complication rates of 4.7% for cardiac RF ablation procedures (American Heart Association, 2023). Technical failure rates of 8.3% were reported in complex tumor ablation cases (Journal of Interventional Radiology, 2022). FDA approval time for new RF ablation devices averaged 18 months in 2022, compared to 12 months for another medical devices. Regulatory compliance costs increased by 28% between 2020-2023 (Medical Device Manufacturers Association).

Category-Wise Acumens

How the Advanced Technology in Disposable RFA Devices Surge the Growth of Disposable Equipment Segment?

The disposable equipment segment dominates the radiofrequency ablation (RFA) devices market, driven by the efficiency and safety of medical procedures. The advanced technology integrated into disposable RFA devices enables the creation of large areas of coagulative necrosis in a controlled and precise manner. These devices are relatively low in toxicity, reducing the likelihood of adverse side effects and minimizing the risk of complications, which further fuels their adoption across various medical specialties.

Disposable RFA devices have a reduced risk of cross-contamination. By using fresh, sterile equipment for each patient, the likelihood of infection or contamination is significantly lowered, enhancing patient safety and boosting confidence in treatment outcomes. Additionally, continuous technological advancements, such as improved electrode designs and the use of advanced materials, are further propelling the growth of this segment, as they enhance the precision, effectiveness, and ease of use of disposable RFA devices.

How does the Increasing Adoption of Effective Treatment for Cancerous Cells Accelerate the Growth of the Oncology Segment?

The oncology segment stands out as dominant in the radiofrequency ablation devices market, driven by its growing adoption as an effective treatment for cancerous cells, particularly in high-risk patients with unresectable or refractory tumors. RFA is increasingly used in surgical oncology to treat various types of cancer, offering a minimally invasive alternative to conventional surgery. Its ability to precisely target cancerous tissues while minimizing damage to surrounding healthy cells has made it a preferred option for addressing both primary and metastatic tumors. This is especially beneficial for patients with multiple tumors or those who cannot undergo open surgery, significantly improving their survival outcomes and overall quality of life.

The rising global prevalence of cancer is a major factor fueling the growth of this segment. As cancer cases increase, so does the demand for advanced, less invasive treatment options like RFA. The technology's ability to reduce potential side effects, shorten recovery times, and deliver precise results has made it a valuable tool in oncology. Moreover, continuous advancements in RFA technology, such as enhanced imaging guidance and the development of multi-electrode systems, have further boosted its efficacy in treating tumors.

Country/Region-wise Acumens

How does the Advanced Healthcare Infrastructure & High Healthcare Spending Accelerate the Growth of the Radiofrequency Ablation Devices Market in North America?

North America substantially dominates the radiofrequency ablation devices market driven by the advanced healthcare infrastructure and high healthcare investment. U.S. healthcare spending reached USD 4.3 Trillion in 2022, with 12% allocated to medical devices and technologies. The number of ambulatory surgery centers performing RF ablation in North America increased by 32% from 2020 to 2023. Canada's healthcare spending on minimally invasive procedures grew by 25% between 2020-2022, with RF ablation accounting for 18% of this growth.

The American Cancer Society reported 1.9 million new cancer cases in 2022, with liver cancer cases increasing 2.8% annually. According to the CDC, cardiovascular diseases affected 48% of adults over 20 in 2022, with 850,000+ requiring interventional procedures. The Heart Rhythm Society documented that atrial fibrillation affects 5.5 million Americans, with RF ablation procedures increasing by 38% from 2020 to 2023

Medicare expanded RF ablation procedure coverage by 35% between 2020-2023, covering 85% of total procedure costs. Private insurance claims for RF ablation procedures increased by 42% from 2020 to 2022. The average reimbursement rate for RF ablation procedures in the U.S. increased from $5,200 in 2020 to $6,800 in 2023.

How does the Rapidly Growing Geriatric Population & Disease Burden Escalate the Growth of the Radiofrequency Ablation Devices Market in the Asia Pacific?

Asia Pacific is anticipated to witness the fastest growth in the radiofrequency ablation devices market during the forecast period owing to the rising aging population and increasing diseases. According to WHO Western Pacific Region, the 65+ population in Asia Pacific reached 300 million in 2022, with an annual growth rate of 3.5%. China reported a 45% increase in liver cancer cases from 2020-2022, with RF ablation being used in 30% of early-stage treatments. Japan's Ministry of Health reported that 42% of its population will be over 60 by 2023, leading to a 28% increase in RF ablation procedures since 2020.

India's healthcare budget increased by 37% in 2022, with 15% allocated to advanced medical technologies including RF ablation (Indian Ministry of Health). South Korea's government provided USD 2.8 Billion in healthcare technology subsidies from 2020-2023, boosting RF ablation device adoption by 42%. Japan's Ministry of Health approved 28% more reimbursement for RF ablation procedures in 2022 compared to 2020, increasing accessibility.

Competitive Landscape

The Radiofrequency Ablation Devices Market is a dynamic and competitive landscape, driven by the increasing adoption of minimally invasive procedures. Key players in this market are continuously innovating to develop advanced RFA systems and accessories.

The organizations are focusing on innovating their product line to serve the vast population in diverse regions. Some of the prominent players operating in the radiofrequency ablation devices market include:

Hologic, Inc.
Medtronic
AngioDynamics, Inc.
Boston Scientific Corporation
Jude Medical, Inc.
Halyard Health, Inc.
Stryker, C. R. Bard, Inc.
AtriCure, Inc.
Johnson & Johnson
BIOTRONIK Schweiz AG

Latest Developments:

In April 2022, AtriCure announced the EnCompass Clamp, a component of its Isolator Synergy ablation system, which provides parallel closure, uniform pressure, and tailored power via synergy radiofrequency, hence improving the efficiency of cardiac tissue ablation during cardiac surgery.
In April 2022, Royal Philips announced the launch of the KODEX-EPD system, which improves imaging and mapping capabilities for RF ablation and includes the Tissue Engagement Viewer as well as support for the Medtronic DiamondTemp system.

1 INTRODUCTION OF GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET

1.1 Overview of the Market
1.2 Scope of Report
1.3 Assumptions

2 EXECUTIVE SUMMARY

3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH

3.1 Data Mining
3.2 Validation
3.3 Primary Interviews
3.4 List of Data Sources

4 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET OUTLOOK

4.1 Overview
4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis

5 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY PRODUCT TYPE

5.1 Overview
5.2 Reusable Equipment
5.3 Disposable Equipment
5.4 Capital Equipment

6 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY APPLICATION

6.1 Overview
6.2 Cardiology & Cardiac Rhythm Management
6.3 Gynecology
6.4 Pain Management
6.5 Surgical Oncology
6.6 Oncology

7 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET, BY GEOGRAPHY

7.1 Overview
7.2 North America
- 7.2.1 U.S.
- 7.2.2 Canada
- 7.2.3 Mexico
7.3 Europe
- 7.3.1 Germany
- 7.3.2 U.K.
- 7.3.3 France
- 7.3.4 Rest of Europe
7.4 Asia Pacific
- 7.4.1 China
- 7.4.2 Japan
- 7.4.3 India
- 7.4.4 Rest of Asia Pacific
7.5 Rest of the World
- 7.5.1 Latin America
- 7.5.2 Middle East and Africa

8 GLOBAL RADIOFREQUENCY ABLATION DEVICES MARKET COMPETITIVE LANDSCAPE

8.1 Overview
8.2 Company Market Ranking
8.3 Key Development Strategies

9 COMPANY PROFILES

9.1 Hologic, Inc.
- 9.1.1 Overview
- 9.1.2 Financial Performance
- 9.1.3 Product Outlook
- 9.1.4 Key Developments
9.2 Medtronic
- 9.2.1 Overview
- 9.2.2 Financial Performance
- 9.2.3 Product Outlook
- 9.2.4 Key Developments
9.3 AngioDynamics, Inc.
- 9.3.1 Overview
- 9.3.2 Financial Performance
- 9.3.3 Product Outlook
- 9.3.4 Key Developments
9.4 Boston Scientific Corporation
- 9.4.1 Overview
- 9.4.2 Financial Performance
- 9.4.3 Product Outlook
- 9.4.4 Key Developments
9.5 St. Jude Medical, Inc.
- 9.5.1 Overview
- 9.5.2 Financial Performance
- 9.5.3 Product Outlook
- 9.5.4 Key Developments
9.6 Halyard Health, Inc.
- 9.6.1 Overview
- 9.6.2 Financial Performance
- 9.6.3 Product Outlook
- 9.6.4 Key Developments
9.7 Stryker, C. R. Bard, Inc.
- 9.7.1 Overview
- 9.7.2 Financial Performance
- 9.7.3 Product Outlook
- 9.7.4 Key Developments
9.8 AtriCure, Inc.
- 9.8.1 Overview
- 9.8.2 Financial Performance
- 9.8.3 Product Outlook
- 9.8.4 Key Developments
9.9 Johnson & Johnson
- 9.9.1 Overview
- 9.9.2 Financial Performance
- 9.9.3 Product Outlook
- 9.9.4 Key Developments
9.10 BIOTRONIK Schweiz AG
- 9.10.1 Overview
- 9.10.2 Financial Performance
- 9.10.3 Product Outlook
- 9.10.4 Key Developments